Centre of Research Excellence in **Pulmonary Fibrosis**

Lung Foundation Australia
Pulmonary Fibrosis Clinical Trials

PACT – Patient
New Clinical Trial and Research

Trial title	BEACON-IPF
Trial synopsis	BEACON-IPF is a Phase 2b clinical study to evaluate the investigational drug bexotegrast (PLN-74809) for the treatment of IPF. The main goal of the study is to find out whether bexotegrast slows down or halts disease progression over a 52-week treatment period by reducing scar formation (fibrosis) of the lungs. BEACON-IPF is recruiting adults aged 40 years and older with Idiopathic Pulmonary Fibrosis (IPF). People are eligible regardless of whether they are or are not taking the medications nintedanib or pirfenidone for their IPF. Participants can continue to take existing medications throughout the study. Participants will be randomly placed into 3 groups to receive either one of two doses of bexotegrast or receive a placebo. Participants will take the different doses of bexotegrast and placebo by mouth, as tablets, once a day.
Investigational medicinal product	Bexotegrast (PLN-74809)
Disease target	Idiopathic Pulmonary Fibrosis (IPF)
Sponsor	Pliant Therapeutics Inc
Duration	The total duration of participation is approximately 1 year
Trial Status	Recruiting
Lead site(s) in Australia	Institute for Respiratory Health - Midland (WA)
Lead site(s) in New Zealand	N/A
Additional sites	• TrialsWest (WA) • Respiratory Clinical Trials (SA) • The Alfred Hospital (VIC)
Contact	pactcoordinator@cre-pf.org.au